Literature DB >> 10887242

Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis.

J Ward1, J A Guthrie, D J Scott, J Atchley, D Wilson, M H Davies, J I Wyatt, P J Robinson.   

Abstract

PURPOSE: To measure the sensitivity and accuracy of double-contrast magnetic resonance (MR) imaging for the diagnosis of hepatocellular carcinoma (HCC) in the cirrhotic liver.
MATERIALS AND METHODS: Twenty-seven patients with MR features of dysplastic nodules and/or HCC were examined. T2-weighted spin-echo and T1-weighted gradient-echo imaging was performed before and after superparamagnetic iron oxide (SPIO) administration and immediately followed by T1-weighted gradient-echo imaging at 10, 40, and 120 seconds after bolus injection of a gadolinium-based contrast material. Nonenhanced, nonenhanced plus SPIO-enhanced, and nonenhanced plus SPIO-enhanced plus gadolinium-enhanced images were reviewed. Alternative-free response receiver operating characteristic (ROC) methodology was used to analyze the results, which were correlated with histopathologic findings after transplantation in 15 patients and at biopsy in 12. Lesions visualized with all three techniques were characterized as a dysplastic nodule or HCC, and ROC analysis was performed.
RESULTS: For all observers, SPIO-enhanced MR imaging (mean accuracy, 0.76) was more accurate than nonenhanced MR imaging (mean accuracy, 0.64) (P <.04), and double-contrast MR imaging (mean accuracy, 0.86) was more accurate than SPIO-enhanced imaging (P <.05). Both types of lesions were correctly characterized with all three techniques, although observer confidence for lesion characterization was greatest with double-contrast MR imaging.
CONCLUSION: Double-contrast MR imaging significantly improves the diagnosis of HCC compared with SPIO-enhanced and nonenhanced imaging (P <.01).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887242     DOI: 10.1148/radiology.216.1.r00jl24154

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  31 in total

Review 1.  [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Authors:  C Stroszczynski; G Gaffke; M Gnauck; F Streitparth; G Wieners; E Lopez-Häninnen
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

2.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

3.  Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning.

Authors:  Hong Zhao; Jin-Lin Yao; Ying Wang; Kang-Rong Zhou
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

4.  Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial.

Authors:  Steven S Raman; Christopher Leary; David A Bluemke; Marco Amendola; Dushyant Sahani; Jeffrey D McTavish; Jeffrey Brody; Eric Outwater; Donald Mitchell; Douglas H Sheafor; Jeff Fidler; Isaac R Francis; Richard C Semelka; Kohkan Shamsi; Simone Gschwend; David R Feldman; Josy Breuer
Journal:  J Comput Assist Tomogr       Date:  2010 Mar-Apr       Impact factor: 1.826

Review 5.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

Review 6.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

7.  Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

Authors:  Yi-Xiang J Wang
Journal:  Quant Imaging Med Surg       Date:  2011-12

Review 8.  Imaging of liver cancer.

Authors:  Ben Ariff; Claire R Lloyd; Sameer Khan; Mohamed Shariff; Andrew V Thillainayagam; Devinder S Bansi; Shahid A Khan; Simon D Taylor-Robinson; Adrian K P Lim
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

9.  Small hypervascular hepatocellular carcinomas: value of "washout" on gadolinium-enhanced dynamic MR imaging compared to superparamagnetic iron oxide-enhanced imaging.

Authors:  Jeong-Sik Yu; Jae-Joon Chung; Joo Hee Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2009-06-10       Impact factor: 5.315

10.  Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging.

Authors:  Hyo-Sung Kwak; Jeong-Min Lee; Young-Kon Kim; Young Hwan Lee; Chong-Soo Kim
Journal:  Eur Radiol       Date:  2004-09-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.